Navigation Links
Zimmer Biomet Announces Resolution with DOJ and SEC Regarding Previously Disclosed Legacy Biomet FCPA Matters

WARSAW, Ind., Jan. 12, 2017 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, announced today that it has concluded agreements with the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed U.S. Foreign Corrupt Practices Act (FCPA) matters involving Biomet, Inc., as well as in relation to the former deferred prosecution agreement and consent to final judgment that Biomet entered into with DOJ and SEC, respectively, on March 26, 2012.  All of the Biomet conduct underlying today's settlement announcement has been reported in the past and occurred years prior to Zimmer Holdings, Inc.'s acquisition of Biomet in June 2015.

As part of the new settlement, the Company has entered into a deferred prosecution agreement with the DOJ with a term of three years; JERDS Luxembourg Holding S.àr.l., the direct parent company of Biomet 3i Mexico SA de CV and an indirect, wholly-owned subsidiary of Biomet, Inc., has entered into a plea agreement with the DOJ; and Biomet, Inc. has entered into a new settlement agreement with the SEC.  The Company has also agreed to oversight by an independent compliance monitor, which will focus on the Company's legacy Biomet operations, as integrated into Zimmer Biomet.  As a result of the resolution, the Company will pay fines, penalties, disgorgement and interest to the DOJ and SEC in an aggregate amount of approximately $30.5 million.  The amounts to be paid were previously recorded in the Company's financial statements and will not impact its 2017 outlook.

"We are pleased to have reached this resolution involving legacy Biomet FCPA compliance matters," said Chad Phipps, Senior Vice President, General Counsel and Secretary of Zimmer Biomet Holdings, Inc.  "Zimmer Biomet is committed to upholding the highest ethical and legal standards in our business practices across the globe, and we look forward to continuing to integrate the legacy Biomet business operations into our robust corporate compliance program."

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare.  We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation.  Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues.  Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries.  For more information, visit or follow Zimmer Biomet on Twitter at  

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Accordingly, such forward-looking statements speak only as of the date made.  Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

To view the original version on PR Newswire, visit:

SOURCE Zimmer Biomet Holdings, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Biomet Announces Fourth Quarter and Full-Year 2016 Preliminary Sales Results
2. Medical Equipment Stocks on Investors Radar -- Hologic, St. Jude Medical, Edwards Lifesciences, and Zimmer Biomet
3. Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2016
4. Zimmer Biomet Announces the Early Tender Results and Upsizing of Its Cash Tender Offers for Certain Outstanding Debt Securities
5. ZIMMER BIOMET (ZBH) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Zimmer Biomet Holdings, Inc.; Encourages all Investors to Contact the Firm for Information
6. Zimmer Biomet Announces Cash Tender Offers for Up to $1.1 Billion Aggregate Purchase Price of Certain Outstanding Debt Securities
7. Medical Equipment Stocks on Investors Radar -- St. Jude Medical, Edwards Lifesciences, Zimmer Biomet, and Stryker
8. Zimmer Biomet Announces Enhancements to Joint Reconstruction Portfolio for the Treatment of Patients with Significant Bone Loss
9. Zimmer Biomet Holdings, Inc. Reports First Quarter 2016 Financial Results
10. Global Orthopedic Surgical Power Tools Market CAGR Growth of 2.59% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Stryker, Zimmer, adeor
11. Zimmer Biomet Secures Exclusive Global Distribution Agreement with CelgenTek Innovations Corporation
Post Your Comments:
(Date:8/5/2020)... ... August 04, 2020 , ... ... testing service since 2016 and has continued to refine their medical device ... traveled onsite to medical device manufacturing facilities to provide testing onsite, at ...
(Date:8/5/2020)... , ... August 04, 2020 , ... Fifty six percent ... respond more quickly and effectively to a healthcare crisis like COVID-19, according to a ... one of the most important issues for older voters this year,” says Mary Johnson, ...
(Date:8/3/2020)... ... August 03, 2020 , ... Seattle’s Infectious Disease ... amend and restate IDRI’s license with Immune Design, a wholly owned subsidiary of ... amendment, the parties have agreed to modify the licensed fields and indications under ...
Breaking Medicine Technology:
(Date:8/3/2020)... ... August 03, 2020 , ... ... of the first patients with first-line advanced pancreatic cancer in a phase 2 ... trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small molecule glycogen ...
(Date:7/31/2020)... ... July 31, 2020 , ... ... plans, is announcing an expansion of clinical & technical capabilities to cover the ... most complete back and joint health solution. , Currently, employers interested in ...
(Date:7/22/2020)... (PRWEB) , ... July 22, 2020 , ... As part of August’s Children’s Eye Health ... for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has released an updated ... National Issues 2nd Edition . The goal of the report is , ...
(Date:7/22/2020)... ... July 22, 2020 , ... ... of infectious diseases for patients and staff. These measures include partnering with ... prevention resources. This timely response is based on guidance from the Centers ...
(Date:7/18/2020)... ... 17, 2020 , ... HMI Performance Incentives’ campaign, Spread Kindness, ... a charitable push put together to help spread positivity in the wake of ... HMI asked individuals in its audience to share stories, answering questions such as ...
Breaking Medicine News(10 mins):